Balanced Electrolyte solution versus Saline Trial for Diabetic KetoAcidosis- Statistical Analysis Plan
Devaux, A.; Li, Q.; Billot, L.; Venkatesh, B.; Ramanan, M.; The BEST-DKA Investigators,
Show abstract
IntroductionFluid therapy is a cornerstone of acute management of diabetic ketoacidosis (DKA), yet the optimal fluid type is unknown. The Balanced Electrolyte Solution versus Saline Trial for Diabetic Ketoacidosis (BEST-DKA) trial has been designed to test the hypothesis that for patients with moderate to severe DKA, fluid therapy with Plasma-Lyte 148, compared with 0.9% saline, will lead to increased days alive and out of hospital to day-28 after enrolment. PurposeTo describe the statistical analysis plan for the BEST-DKA trial. Design, settings and participants: BEST-DKA is a currently recruiting cluster-randomised, crossover randomised controlled trial which will recruit a minimum of 400 patients with moderate or severe DKA at 22 hospitals in Australia, which will provide >91.4% power to detect a change of 2 days in the primary outcome, days alive and out of hospital to day-28 after enrolment. Hospitals will be randomised to either blinded saline or Plasma-Lyte 148 for a 12-month period, and then crossover to the alternate fluid for the next 12-month period. ConclusionBEST-DKA started enrolment in March 2024 and recruitment is on target with scheduled completion in July 2026. 1 Administrative information1.1 Study identifiersO_LIClinicalTrials.gov register Identifier: NCT05752279. C_LI 1.2 Revision history O_TBL View this table: org.highwire.dtl.DTLVardef@1260f2forg.highwire.dtl.DTLVardef@1aee8b0org.highwire.dtl.DTLVardef@2e86f5org.highwire.dtl.DTLVardef@9e6e1aorg.highwire.dtl.DTLVardef@14ea7bf_HPS_FORMAT_FIGEXP M_TBL C_TBL 1.3 Contributors to the statistical analysis plan1.3.1 Roles and responsibilities O_TBL View this table: org.highwire.dtl.DTLVardef@e72de5org.highwire.dtl.DTLVardef@17617e6org.highwire.dtl.DTLVardef@1b3114org.highwire.dtl.DTLVardef@1332eaborg.highwire.dtl.DTLVardef@13cf3bb_HPS_FORMAT_FIGEXP M_TBL C_TBL 1.3.2 ApprovalsThe undersigned have reviewed this plan and approve it as final. They find it to be consistent with the requirements of the protocol as it applies to their respective areas. They also find it to be compliant with ICH-E9 principles and in particular confirm that this analysis plan was developed in a completely blinded manner, i.e. without knowledge of the effect of the intervention(s) being assessed. O_TBL View this table: org.highwire.dtl.DTLVardef@a5b932org.highwire.dtl.DTLVardef@21b229org.highwire.dtl.DTLVardef@37cbdforg.highwire.dtl.DTLVardef@129af05org.highwire.dtl.DTLVardef@1a1b175_HPS_FORMAT_FIGEXP M_TBL C_TBL
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world effects of ACE inhibitors and Angiotensin Receptor Blockers: protocol for an emulation study of the ONTARGET trial using electronic health records 94%
- The iDiabetes Platform: Enhanced Phenotyping of Patients with Diabetes for Precision Diagnosis, Prognosis and Treatment- study protocol for a cluster-randomised controlled study 94%
- CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults 94%
Similar papers in this journal
- Statistical Analysis Plan for the Stepped-wedge Cluster Randomized Controlled Trial of Electronic Early Notification of Sepsis in Hospitalized Ward Patients (SCREEN): a study protocol for a stepped-wedge cluster randomized controlled trial 95%
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 95%
- Decision support system to evaluate VENTilation in the Acute Respiratory Distress Syndrome (DeVENT study) – Trial Protocol 94%
Similar papers in this journal
- Randomised, controlled, feasibility trial comparing vasopressor infusion administered via peripheral cannula versus central venous catheter for critically ill adults: a study protocol 95%
- STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol 95%
- Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU) 93%
Similar papers in this journal
- Prophylaxis for covid-19: living systematic review and network meta-analysis 92%
- Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) 91%
- No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial 91%
Similar papers in this journal
- Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform 91%
- The consequences of adjustment, correction and selection in genome-wide association studies used for two-sample Mendelian randomization 88%
- Quantitative biomarker profiling of serum samples in the By-Band-Sleeve trial 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.